Converted by EDGARwiz

[novogenannouncesestablish001.jpg]

ASX RELEASE

7 August 2013

Novogen Announces Appointment of Chairman of its Medical Advisory

Board

Novogen today announces the appointment of Professor Paul de Souza as

Chairman of its Medical Advisory Board.

The purpose of the Board is to advise the Company on the design and conduct of

its clinical trials. The membership of the Board will be honorary, enabling the

various members also to act as Clinical Trial Investigators where appropriate.

Professor De Souza is the Foundation Professor of Medical Oncology at the

University of Western Sydney, Director of the Translational Cancer Research

Unit of The Ingham Institute of Medical Research, Conjoint Professor in the

Faculty of Medicine of the University of NSW, and Director of the Department of

Medical Oncology at Liverpool Hospital.

Other members of the Board yet to be appointed will comprise experts drawn

from Australia, USA and Europe.

Novogen CEO, Dr Graham Kelly, said today, “Professor de Souza’s appointment is

timely as we now stand on the verge of bringing CS-6 into the clinic. With CS-6

continuing to meet its targets in its current pre-clinical program, we find

ourselves in a position of being able to bring the drug into the clinic earlier than

originally predicted. Professor de Souza’s considerable expertise in translational

research and clinical trial design will be invaluable in guiding the Company

through this next important step.”

“Our goal is to conduct a joint Phase 1a/1b in Australia and Hong Kong in

patients with late-stage cancer with a focus on Temozolomide-resistant

glioblastoma multiforme and carboplatin-refractory ovarian cancer. Naturally

we will be applying to the FDA to conduct clinical studies in the US in 2014, but

the strategy of conducting our inaugural Phase 1 clinical studies in Australia and

Hong Kong affords considerable time and cost savings,” Kelly added.

About Novogen

Novogen Ltd is a biotechnology company whose shares trade on both the

Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol ‘NVGN’). The

Company is based in Sydney, Australia and in Manhattan, USA, and is focused on

the development of novel anti-cancer drugs. The Company’s inaugural drug

candidate is CS-6, with a pipeline of related drugs in development.

About CS-6

CS-6 belongs to a new class of drug candidates that target a mutation concerned

with the bioenergetics of a cell and which Novogen believes to be a fundamental

and key part of carcinogenesis. Inhibition of this mutation provides the potential

to act against all forms of cancer, including both cancer stem cells and their

daughter cells, and against cells with multiple mechanisms of drug resistance.

CS-6 shows broad anti-proliferative and cytotoxic activity against all human

cancer cells that is has been tested against and ovarian cancer stem cells. CS-6

also has been designed deliberately to meet the major known criteria for

crossing the blood-brain barrier, and for that reason is being developed for the

treatment of glioblastoma multiforme, the main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave Hornsby NSW 2077 AUSTRALIA

PO Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA

E: Graham.Kelly@novogen.com

Further information is available on the Company’s web site, www.novogen.com